UY39005A - Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting - Google Patents
Compuestos y composiciones para tratar afecciones asociadas con la actividad de stingInfo
- Publication number
- UY39005A UY39005A UY0001039005A UY39005A UY39005A UY 39005 A UY39005 A UY 39005A UY 0001039005 A UY0001039005 A UY 0001039005A UY 39005 A UY39005 A UY 39005A UY 39005 A UY39005 A UY 39005A
- Authority
- UY
- Uruguay
- Prior art keywords
- sting
- compositions
- compounds
- conditions associated
- treat conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta descripción caracteriza entidades químicas (por ejemplo, un compuesto o una sal farmacéuticamente aceptable, y/o hidrato, y/o co-cristal, y/o combinación de fármaco del compuesto) que inhibe (por ejemplo, antagoniza) el Estimulador de Genes de Interferón (STING). Tales entidades químicas son útiles, por ejemplo, para tratar una condición, enfermedad o trastorno en el cual la activación de STING incrementada (por ejemplo, excesiva) (por ejemplo, señalización de STING) contribuye a la patología y/o síntomas y/o progresión de la afección, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un humano). Esta descripción también caracteriza composiciones que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955853P | 2019-12-31 | 2019-12-31 | |
| US202063090547P | 2020-10-12 | 2020-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39005A true UY39005A (es) | 2021-07-30 |
Family
ID=74550729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039005A UY39005A (es) | 2019-12-31 | 2020-12-30 | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230115274A1 (es) |
| EP (1) | EP4085061A1 (es) |
| JP (1) | JP2023509421A (es) |
| CN (1) | CN115279770A (es) |
| TW (1) | TW202136255A (es) |
| UY (1) | UY39005A (es) |
| WO (1) | WO2021138419A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202014408A (zh) | 2018-07-03 | 2020-04-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病症的化合物及組合物 |
| CN117597117A (zh) | 2020-12-22 | 2024-02-23 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| CN117412745A (zh) | 2020-12-22 | 2024-01-16 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| WO2024032597A1 (zh) * | 2022-08-11 | 2024-02-15 | 杭州中美华东制药有限公司 | 具有sting抑制作用的酰胺类化合物及其药物组合物和用途 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024089155A1 (en) * | 2022-10-28 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as sting antagonists |
| CN116023321A (zh) * | 2022-12-30 | 2023-04-28 | 中国药科大学 | Sting抑制剂前药及其医药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| CA2927009C (en) | 2013-10-21 | 2019-04-23 | Drexel University | Use of sting agonists to treat chronic hepatitis b virus infection |
| EP3556362A1 (en) * | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| TW202014408A (zh) | 2018-07-03 | 2020-04-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病症的化合物及組合物 |
-
2020
- 2020-12-30 US US17/789,623 patent/US20230115274A1/en active Pending
- 2020-12-30 TW TW109146786A patent/TW202136255A/zh unknown
- 2020-12-30 WO PCT/US2020/067463 patent/WO2021138419A1/en unknown
- 2020-12-30 UY UY0001039005A patent/UY39005A/es unknown
- 2020-12-30 JP JP2022540327A patent/JP2023509421A/ja active Pending
- 2020-12-30 CN CN202080097812.6A patent/CN115279770A/zh active Pending
- 2020-12-30 EP EP20849007.8A patent/EP4085061A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202136255A (zh) | 2021-10-01 |
| WO2021138419A1 (en) | 2021-07-08 |
| JP2023509421A (ja) | 2023-03-08 |
| CN115279770A (zh) | 2022-11-01 |
| EP4085061A1 (en) | 2022-11-09 |
| US20230115274A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39005A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY38751A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY39006A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| UY38905A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting | |
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CO2019008932A2 (es) | Imidazo-quinolinas sustituidas como moduladores de nlrp3 | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| MX2018012249A (es) | Moduladores de nlpr3. | |
| CU20210094A7 (es) | Inhibidores del inflamasoma nlrp3 | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| UY39328A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| CR20180185A (es) | Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| UY39608A (es) | Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| CO2017012545A2 (es) | Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ) | |
| PH12019501074A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| MX2020003868A (es) | Compuesto heterociclico como inhibidor de proteina quinasa. | |
| DOP2023000251A (es) | Compuestos oligoméricos que inhiben la expresión de hsd17b13 | |
| PH12018502378A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| CL2019000190A1 (es) | Tratamiento y prevención de los trastornos del sueño. | |
| EA202190395A1 (ru) | Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств | |
| CL2019000661A1 (es) | Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica. |